<DOC>
<DOCNO>EP-0638568</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31495	C07D41306	C07D40100	A61K31495	A61P310	C07D40106	A61K31505	C07D41304	A61P308	C07D40306	A61P300	C07D40300	A61K31505	C07D41300	C07D40304	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	C07D	A61K	A61P	C07D	A61K	C07D	A61P	C07D	A61P	C07D	A61K	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D413	C07D401	A61K31	A61P3	C07D401	A61K31	C07D413	A61P3	C07D403	A61P3	C07D403	A61K31	C07D413	C07D403	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of general formula (I): 
<
IMAGE
>
  in which     - A represents the radical 
<
IMAGE
>
     - X represents N-R4 or oxygen, - and R1, R2, R3, R4, R5, n and m are as defined in the description.     These compounds find their application in therapeutics in the treatment of non-insulin-dependent diabetes.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I): 

 
in which : 


R
1
 and R
2
, each independently of the other, are 
selected from hydrogen and alkyl, cycloalkyl, monocycloalkylalkyl, 

dicycloalkylalkyl, aryl and arylalkyl 
radicals, each of those radicals being optio
nally 
substituted, 
R
3
 is selected from hydrogen and an alkyl radical, 
n has a value selected from 0, 1 and 2, and 
A represents the radical 

 
in which 


X represents oxygen or the group N-R
4
, 
m has a value selected from 1 and 2, 
R
4
 is selected from hydrogen and optionally 
substituted alkyl, alkoxycarbonyl and aryloxycarbonyl 

radicals, and 
R
5
 is selected from hydrogen and an alkyl radical, 
  
 

wherein: 
the terms "alkyl", "alkoxy", "monocycloalkylalkyl", 
"dicycloalkylalkyl", "arylalkyl" and "alkoxycarbonyl" 

denote radicals the hydrocarbon chain of which contains 
from 1 to 10 carbon atoms in a straight or branched 

chain, 
the term "cycloalkyl" denotes cyclic hydrocarbon 
radicals containing from 3 to 8 carbon atoms, 
the terms "aryl", "arylalkyl" and "aryloxycarbonyl" 
relate to radicals the aromatic part of which is a 

phenyl radical or a naphthyl radical, and 
the expression "optionally substituted" means that the 
radicals so described may be substituted by one or more 

chemical entities selected from alkyl, hydroxy, alkoxy, 
halogen, haloalkyl, polyhaloalkyl, nitro, amino, alkylamino 

and polyalkylamino radicals, 
 
their stereoisomers, N-oxides and addition salts with a 

pharmaceutically acceptable acid or base. 
Compounds according to claim 1 in which X represents 
the group -N-R
4
 and m is 1, their stereoisomers, N-oxides 
and addition salts with a pharmaceutically acceptable 

acid or base. 
Compounds according to claim 1 in which X represents 
oxygen and m is 1, their stereoisomers, N-oxides and 

addition salts with a pharmaceutically acceptable acid or 
base. 
A compound according to either claim 1 or claim 2 
which is 1-(2,4-dichlorobenzyl)-2-(4,5-dihydro[1H]
-imidazol-2-yl)-4-methylpiperazine,  
 

its stereoisomers, N-oxides and addition salts with a 
pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 2 
which is 1-methyl-2-(4,5-dihydro[1H]
imidazol-2-yl)-4-(2-chlorobenzyl)piperazine, 
its stereoisomers, N-oxides and addition salts with a 

pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 2 
which is 1-methyl-2-(4,5-dihydro[1H]
imidazol-2-yl)-4-(2,4-dichlorobenzyl)piperazine, 
its stereoisomers, N-oxides and addition salts with a 

pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 2 
which is 1,4-dibenzyl-2-[(4,5-dihydro[1H]
imidazol-2-yl)-methyl]piperazine, 

its stereoisomers, N-oxides and addition salts with a 
pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 3 
which is 1-methyl-4-(2-chlorobenzyl)-2-(4,5-dihydro[1H]
-oxazol-2-yl)piperazine, 
its stereoisomers, N-oxides and addition salts with a 

pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 3 
which is 1,4-dibenzyl-2-[(4,5-dihydro[1H]
oxazol-2-yl)-methyl]piperazine, 

its stereoisomers, N-oxides and addition salts with a 
pharmaceutically acceptable acid. 
A compound according to either claim 1 or claim 2 
which is 1,4-diisopropyl-2-(4,5-dihydro[1H]
imidazol-2-yl)piperazine,  
 

its stereoisomers, N-oxides and addition salts with a 
pharmaceutically acceptable acid. 
Process for the preparation of compounds of 
formula (I) according to claim 1, characterised in that: 


a) - the compound of formula (II): 

C
6
H
5
-CH
2
-NH-CH
2
-CH
2
-NH-CH
2
-C
6
H
5
 
is brought to reflux in an aromatic solvent in the 

presence of triethylamine with the dibromide of 
formula (III): 


 
in which Alk represents a linear or branched alkyl 

radical having from 1 to 4 carbon atoms,
 
to give the compound of formula (IV): 


 
in which Alk is as defined above,
 
which is then debenzylated by the action of hydrogen in 

the presence of a catalyst to give the compound of 
formula (V): 


  
 

in which Alk is as defined above,
 
which is then converted into the compound of formula 

(Va), (Vb) or (Vc): 

 
in which Arak represents an optionally substituted 

arylalkyl radical as defined above, and Alk is as defined 
above, 


for the compound of formula (Va):
 
after protection of the nitrogen atom in the 4-position 

by triphenylmethyl chloride in a suitable solvent, in the 
presence of triethylamine, by treatment with Arak-Cl in 

the presence of potassium carbonate and of a catalytic 
amount of potassium iodide, in a suitable solvent, and 

then deprotection of the nitrogen atom in the 4-position 
by means of gaseous hydrogen chloride in a suitable 

solvent, 
for the compounds of formulae (Vb) and (Vc):
 
by treatment of the compound of formula (V) directly with 

Arak-Cl in toluene at reflux in the presence of triethylamine, 
and then separation of the mono- and disubstituted 

compounds by chromatography over a silica 
gel column, 
b) - or, the compound of formula (VI):  
 


 
is optionally treated with a ketone or an aldehyde, in an 

acidic and alcoholic medium, the ketone or aldehyde 
chosen being the homologue of the radical R'
1
 (R'
1
 
having the same definition as R
1
, with the exception of 
hydrogen) that is to be bonded to the nitrogen atom, in 

order to obtain the compound of formula (VII): 

 
in which R'
1
 is as defined above,
 
which compounds of formulae (VI) and (VII), when treated 

with a chlorinating agent, yield the corresponding 
chlorinated compounds and then, under the action of a 

saturated aqueous ammonia solution, yield the compound of 
formula (VIII): 


 
in which R
1
 is as defined above,
 
which compound is then optionally treated, like the 

compound of formula (VI), with the homologue of the 
radical R'
2
 (R'
2
 having the same definition as R
2
, with 
the exception of hydrogen) in the form of an aldehyde or 

ketone, and, after hydrogenation of the double bond that 
is formed, yields the diamine of formula (IX):  

 

 
in which R
1
 and R'
2
 are as defined above,
 
the compou
nds of formulae (VIII) and (IX) then being 
debenzylated according to the process described for the 

compound of formula (IV) and then treated with the 
dibromide of formula (III) described above to give, after 

separation of any isomers by chromatography and/or 
crystallisation, the compound of formula (X): 


 
in which R
1
, R
2
 and Alk are as defined above, 
c) - or, the compound of formula (VI): 

 
is optionally treated with a ketone or an aldehyde, in an 

acidic and alcoholic medium, the ketone or aldehyde 
chosen being the homologue of the radical R'
2
 (R'
2
 
having the same definition as R
2
, with the exception of 
hydrogen) that is to be bonded to the nitrogen atom, in 

order to obtain the compound of formula (XI): 

  
 

in which R'
2
 is as defined above,
 
which compounds of formulae (VI) and (XI), when treated 

with a chlorinating agent, yield the corresponding 
chlorinated compounds which, when treated with benzylamine, 

yield the diamine of formula (XII): 

 
in which R
2
 is as defined above,
 
which, by reaction with a halogenated compound of 

formula (XIII): 

 
in which X represents a halogen atom and Alk is as 

defined above,
 
yields the diamine of formula (XIV): 


 
in which Alk and R
2
 are as defined above,
 
which, after metallisation and reaction with a halogenated 

compound of formula (XV): 

X-R
3
 
in which X and R
3
 are as defined above,
  
 

yields the diamine of formula (XVI): 

 
in which R
2
, R
3
 and Alk are as defined above,
 
which, after catalytic debenzylation and cyclisation, 

yields the piperazinone of formula (XVII): 

 
in which R
2
, R
3
 and Alk are as defined above,
 
which: 


either by the action of aldehyde or ketone precursors 
of the radical R'
1
 according to the method described 
above, 
or by direct alkylation with a halogenated compound of 
formula (XVIII): 


R'
1
-X
 
in which R'
1
 and X are as defined above, 
 
yields the piperazinone of the general formula (XIX): 


  
 

in which R'
1
, R
2
, R
3
 and Alk are as defined above,
 
which piperazinones of formulae (XIX) and (XVII), by 

reduction with boron hydrides, yield the piperazine of 
formula (XX): 


 
in which R
1
, R
2
, R
3
 and Alk are as defined above,
 
it likewise being possible for the secondary amines of 

the compounds of formulae (V), (Va) and (Vb) to be 
substituted: 


either by the action of aldehyde or ketone precursors 
of the radicals R'
1
 or R'
2
 according to the method 
described above, 
or by direct alkylation with a halogenated compound of 
formula (XXI): 


R-X
 
in which R has the same definition as R'
1
 or R'
2
 and X 
represents a halogen,
 
with, in the case of the compounds of formula (V), 

optional protection beforehand of the most reactive 
nitrogen atom by a triphenylmethyl group, as indicated 

for the preparation of the compound of formula (Va), 
 
the compounds of formulae (V), (Va), (Vb) and (Vc), their 

optional products of substitutions as discussed above, 
and the compounds of formula (X) likewise forming part of  

 
the compounds of formula (XX),
 
which compounds of formula (XX) may optionally be 

converted into their higher homologues of 
formula (XXII): 


 
in which R
1
, R
2
, R
3
 and Alk are as defined above,
 
by treatment with a reducing agent, in order to convert 

the ester function into an alcohol function, and then 
chlorination, followed by treatment with an alkaline 

earth metal cyanide, and finally conversion of the 
resulting nitrile into an ester by the action of an 

alcohol in an acidic medium,
 
which compound of formula (XXII), when optionally 

subjected to the same treatment, yields the homologue of 
formula (XXIII): 


 
in which R
1
, R
2
, R
3
 and Alk are as defined above,
 
all the compounds of formulae (XX), (XXII) and (XXIII) 

forming the compounds of formula (XXIV) in their 
entirety: 


  
 

in which R
1
, R
2
, R
3
, Alk and n are as defined above, 
which compounds of formula (XXIV) are subjected: 


either
 : a) to the action of a diamine of formula (XXV): 

 
in which R
4
, R
5
 and m are as defined above,
 
in the presence of a trialkylaluminium, in an anhydrous 

aprotic solvent, to give the compound of formula (Ia): 

 
in which R
1
, R
2
, R
3
, R
4
, R
5
, n and m are as defined 
above, 
or
 : b) to the action of the compound of formula (XXVI): 

 
in which R
5
 and m are as defined above, 
 
which compound is obtained from the corresponding α-ω-hydroxy-amine, 

the amine function of which has previously 
been protected by conversion to N,N-dibenzyl-α-ω-hydroxy-amine, 

by the action of benzyl chloride, and then 
protection of the alcohol function by dihydropyran, and  

 
then hydrogenolysis in the presence of palladium-on-carbon 

in order to free the amine function,
 
the compound of formula (XXVI) reacting with the compound 

of formula (XXIV) under the same conditions as the 
compound of formula (XXV) to give the compound of 

formula (XXVII): 

 
in which R
1
, R
2
, R
3
, R
5
, n and m are as defined above,
 
the alcohol function of which compound is freed in an 

acidic alcoholic medium and then converted into the 

corresponding chloride by the action of thionyl chloride 
in order to permit the desired cyclisation, in a basic 

medium, and obtain the compound of formula (Ib): 

 
in which R
1
, R
2
, R
3
, R
5
, n and m are as defined above,
 
all the compounds of formulae (Ia) and (Ib) forming the 

compounds of formula (I) in their entirety, which 
compounds are purified and, optionally, separated into 

their stereoisomers by a conventional separation method 
and which are, if desired, converted into their N-oxides 

or into their addition salts with a pharmaceutically 
acceptable acid or base. 
Pharmaceutical compositions containing as active 
ingredient at least one compound according to any one of 

claims 1 to 10, on its own or in combination with one or 
more inert, non-toxic, pharmaceutically acceptable 

carriers. 
Pharmaceutical compositions according to claim 12 
that increase glucose tolerance in patients suffering 

from non-insulin-dependent diabetes and that can be used 
in the treatment of the said diabetes. 
</CLAIMS>
</TEXT>
</DOC>
